Tailored 96-well μElution solid-phase extraction combined with UFLC-MS/MS: a significantly improved approach for determination of free 3-nitrotyrosine in human urine

We developed and validated a simple and fast UFLC-MS/MS method for the accurate determination of 3-nitrotyrosine (3-NT) in human urine as a noninvasive biomarker for oxidative stress. The method, involving tailored 96-well μElution solid-phase extraction (SPE) combined with UFLC-MS/MS, allows 3-NT to be determined in biological samples without the need for hydrolysis, derivatization, evaporation, and two-dimensional LC for the first time. Using ammonium acetate (pH?9, 25 mM) as an elution buffer was found to improve SPE selectivity. Fast chromatographic elution of 3-NT with a total run time of 7 min was achieved on a PFPP column (150 mm?×?2.1 mm, 3 μm). This fine-tuned integrated method delivered significantly improved throughput, specificity, and sensitivity while reducing the matrix effect, solvent usage, and waste disposal. Using this simple and rapid method, two plates of urine samples (n?=?192) can be processed within 24 h. The lower limit of quantification for 3-NT is 10 pg/mL, which represents a notable sensitivity enhancement over reported methods. Less than 6.0 % variations for intraday and interday assay precisions and 97.7–106.3 % for accuracies in terms of recovery were obtained. The applicability and reliability of the method were demonstrated by determining the reference range in human urine for 82 healthy people. Considering the noninvasive and inexpensive nature of urine sampling, this novel method could be used to re-evaluate the role of 3-NT as an oxidative stress biomarker in pre-clinical and clinical studies.     

Simple, Rapid, and Accurate RP-HPLC Method for Determination of Cystine in Human Urine after Derivatization with Dansyl Chloride

An accurate, simple, and sensitive reversed-phase high-performance liquid chromatographic method, with loratadine as internal standard (IS) and UV detection at 286 nm, has been developed for deterination of cystine in human urine. The major innovations of the method include use of acrylonitrile to protect cysteine from oxidization to cystine, separation of cysteine, as the dansyl derivative, from cystine, and use of isocratic elution instead of gradient elution to reduce the time and cost of serial analysis. The mobile phase was 0.05 M sodium acetate–methanol, 35:65 (v/v), adjusted to pH 3.5 with 2.5 M citric acid, at a flow rate of 1.0 mL min^?1. The retention times of cystine and the IS were 16.6 and 19.9 min, respectively. The limit of detection for cystine was 0.3 mg L^?1. Extraction recovery of cystine was >85.6%. Intra-day and inter-day precision (RSD) for cystine were below 4.3 and 8.5%, respectively. There was no chromatographic interference from other α-amino acids present in mammalian proteins, or from other urine components. The calibration plot for the cystine derivative was linear in the range 1–500 mg L^?1 and the correlation coefficient was 0.9992. The method was validated appropriately and successfully used for determination of cystine in human urine.     

HPLC estimation of iothalamate to measure glomerular filtration rate in humans

Glomerular filtration rate (GFR) is usually determined by estimation of iothalamate (IOT) clearance. We have developed and validated an accurate and robust method for the analysis of IOT in human plasma and urine. The mobile phase consisted of methanol and 50 mM sodium phosphate (10:90; v/v). Flow rate was 1.2 mL/min on a C18 reverse phase column, Synergi-hydro (250 × 4.6 mm) 4 µm 80 Å, with an ultraviolet detector set to 254 nm. Acetonitrile was used for the deproteination and extraction of IOT from human plasma and urine. Precision and accuracy were within 15% for IOT in both plasma and urine. The recoveries of IOT in urine and plasma ranged between 93.14% and 114.74 and 96.04–118.38%, respectively. The linear range for urine and plasma assays were 25–1500 and 1–150 µg/mL respectively. The lower limits of detection were 0.5 µg/mL for both urine and plasma, with no interference from plasma and urine matices. This method has been fully validated according to FDA guidelines and the new HPLC assay has been applied to a new formulation of IOT (Conray? 43), to calculate GFR in healthy volunteers. The new method is simple, less expensive and it would be instrumental in future clinical and pharmacokinetic studies of iothalamate in kidney patients.     

LC Determination of Ketorolac in Human Plasma and Urine for Application to Pharmacokinetic Studies

A simple, specific and sensitive liquid chromatographic method has been developed for the assay of ketorolac in human plasma and urine. The clean-up of plasma and urine samples were carried out by protein precipitation procedure and liquid–liquid extraction, respectively. Separation was performed by a Waters sunfire C₁₈ reversed-phase column maintained at 35 °C. The mobile phase was a mixture of 0.02 M phosphate buffer (pH adjusted to 4.5 for plasma samples and to 3.5 for urine samples) and acetonitrile (70:30, v/v) at a flow rate of 1.0 mL min⁻¹. The UV detector was set at 315 nm. Nevirapine was used as an internal standard in the assay of urine sample. The method was validated over the concentration range of 0.05–8 and 0.1–10 μg mL⁻¹ for ketorolac in human plasma and urine, respectively. The limits of detection were 0.02 and 0.04 μg mL⁻¹ for plasma and urine estimation at a signal-to-noise ratio of 3. The limits of quantification were 0.05 and 0.1 μg mL⁻¹ for plasma and urine, respectively. The extraction recoveries were found to be 99.3 ± 4.2 and 80.3 ± 3.7% for plasma and urine, respectively. The intra-day and inter-day standard deviations were less than 0.5. The method indicated good performance in terms of specificity, linearity, detection and quantification limits, precision and accuracy. This assay demonstrated to be applicable for clinical pharmacokinetic studies.

     

LC Determination of Ketorolac in Human Plasma and Urine for Application to Pharmacokinetic Studies

A simple, specific and sensitive liquid chromatographic method has been developed for the assay of ketorolac in human plasma and urine. The clean-up of plasma and urine samples were carried out by protein precipitation procedure and liquid–liquid extraction, respectively. Separation was performed by a Waters sunfire C₁₈ reversed-phase column maintained at 35 °C. The mobile phase was a mixture of 0.02 M phosphate buffer (pH adjusted to 4.5 for plasma samples and to 3.5 for urine samples) and acetonitrile (70:30, v/v) at a flow rate of 1.0 mL min^?1. The UV detector was set at 315 nm. Nevirapine was used as an internal standard in the assay of urine sample. The method was validated over the concentration range of 0.05–8 and 0.1–10 μg mL^?1 for ketorolac in human plasma and urine, respectively. The limits of detection were 0.02 and 0.04 μg mL^?1 for plasma and urine estimation at a signal-to-noise ratio of 3. The limits of quantification were 0.05 and 0.1 μg mL^?1 for plasma and urine, respectively. The extraction recoveries were found to be 99.3 ± 4.2 and 80.3 ± 3.7% for plasma and urine, respectively. The intra-day and inter-day standard deviations were less than 0.5. The method indicated good performance in terms of specificity, linearity, detection and quantification limits, precision and accuracy. This assay demonstrated to be applicable for clinical pharmacokinetic studies.     

Quantitative and Qualitative Analysis of CKD-501, Lobeglitazone,in Human Plasma and Urine Using LC–MS/MS and Its Application to a Pharmacokinetic Study

A simple, rapid and sensitive LC–MS/MS method in positive ion mode was developed and validated to determine CKD-501, lobeglitazone, in human plasma and urine using glipizide as an internal standard (IS). Lobeglitazone is a novel thiazolidinedione (TZDs)-based peroxisome proliferator-activated receptor (PPAR) agonist, used for the management of type-2 diabetes. After mixing the IS, dissolved in acetonitrile, with a plasma or urine sample containing lobeglitazone, 10 μL of supernatant was injected into the LC–MS/MS system. Quantification was performed in the multiple reaction monitoring (MRM) mode using transition of 481.5 → 152.2 (m/z) for lobeglitazone and 446.1 → 321.2 (m/z) for the IS. The method showed good linearity over concentration ranges of 0.5–1,000 ng mL⁻¹ for plasma and 0.2–250 ng mL⁻¹ for urine (r ² ≥ 0.9996). The mean percent extraction recovery of lobeglitazone was 90.8 % for plasma and 87.3 % for urine, while the recoveries of the IS were greater than 86.4 % for both. The intra-day and inter-day precision of plasma ranged from 1.1 to 3.7 and 2.5 to 3.3 % (RSD), respectively, and the intra- and inter-day precision of urine ranged from 1.5 to 2.7 and 3.2 to 3.5 %, respectively. This method is simple, sensitive, and applicable for the pharmacokinetic study of lobeglitazone in human plasma. Most of the urine concentrations of lobeglitazone were below the LLOQ because the lobeglitazone is extensively metabolized.

     

Optimization and Validation of a Capillary MEKC Method for Determination of Proteins in Urine

Proteinuria, i.e. increased excretion of proteins in urine, is a common sign indicating renal or urinary tract diseases. In this study, a fast and simple procedure for urine sample preparation and capillary micellar electrokinetic chromatographic analysis is presented, without any sample pretreatment prior to the analysis. The developed MEKC method was employed for simultaneous determination of albumin (ALB), haemoglobin (HGB), and myoglobin (MYO) in human urine samples obtained from patients with diagnosed proteinuria. Optimum conditions for detection and separation of ALB, HGB, and MYO are 50 mmol L⁻¹ borate buffer containing 20 mmol L⁻¹ SDS (pH 9.3), injection 40 mbar × 20 s, voltage 25 kV, temperature 30 °C, and detection wavelength 200 nm. The method was shown to be specific, accurate, linear (correlation coefficients r ² > 0.99), and precise (RSD below 3.75 and 7.23% for migration time and peak area, respectively). Multi-variable-at-a-time (MVAT) approach for robustness testing shows no significant variations in accuracy, specificity, and precision as RSD values were lower than 5 and 10% for migration time and peak area, respectively. The presented method is applicable for routine analyses of urine samples as a screening method for patients with excess ALB, HGB, and MYO.

     

Analysis of Pazufloxacin Mesilate in Human Plasma and Urine by LC with Fluorescence and UV Detection,and Its Application to Pharmacokinetic Study

A liquid chromatographic method for analysis of pazufloxacin mesilate in human plasma and urine has been developed and validated for selectivity, sensitivity, accuracy, precision, and stability in pharmacokinetic analysis. The sensitivity of the method was 0.02 μg mL^?1 in plasma and 0.5 μg mL^?1 in urine, with overall intra-day and inter-day precision (RSD < 10%) and accuracy (90–120%) acceptable for clinical pharmacokinetic analysis. Recovery from plasma and urine was 80–110% for both pazufloxacin mesilate and enoxacin, the internal standard. Pazufloxacin was stable in both plasma and urine, with no significant degradation under four different conditions. The method was successfully used in a preliminary study of the bioavailability of pazufloxacin mesilate in healthy human volunteers after intravenous administration of 300 and 500 mg.     

Analysis of anabolic androgenic steroids in urine by full-capillary sample injection combined with a sweeping CE stacking method

This study describes an on-line stacking CE approach by sweeping with whole capillary sample filling for analyzing five anabolic androgenic steroids in urine samples. The five anabolic steroids for detection were androstenedione, testosterone, epitestosterone, boldenone, and clostebol. Anabolic androgenic steroids are abused in sport doping because they can promote muscle growth. Therefore, a sensitive detection method is imperatively required for monitoring the urine samples of athletes. In this research, an interesting and reliable stacking capillary electrophoresis method was established for analysis of anabolic steroids in urine. After liquid–liquid extraction by n-hexane, the supernatant was dried and reconstituted with 30 mM phosphate buffer (pH 5.00) and loaded into the capillary by hydrodynamic injection (10 psi, 99.9 s). The stacking and separation were simultaneously accomplished at ?20 kV in phosphate buffer (30 mM, pH 5.0) containing 100 mM sodium dodecyl sulfate and 40 % methanol. During the method validation, calibration curves were linear (r?≥?0.990) over a range of 50–1,000 ng/mL for the five analytes. In the evaluation of precision and accuracy for this method, the absolute values of the RSD and the RE in the intra-day (n?=?3) and inter-day (n?=?5) analyses were all less than 6.6 %. The limit of detection for the five analytes was 30 ng/mL (S/N?=?5, sampling 99.9 s at 10 psi). Compared with simple MECK, this stacking method possessed a 108- to 175-fold increase in sensitivity. This simple and sensitive stacking method could be used as a powerful tool for monitoring the illegal use of doping.     

Determination of Copper in Human Urine by RP-LC After Pre-column Derivatization with Neocuproine and Use of Monolithic Column

A selective sensitive RP-LC–UV/VIS method with pre-column derivatization was developed for the determination of copper in human urine at a trace level. This method is based on the selective reaction of 2,9-dimethyl-1,10-phenanthroline (neocuproine) with copper(I) to produce a yellow-orange hydrophobic complex in a neutral or slightly acidic buffer solution (adjusted to pH 5.9). Copper(II) was reduced to copper(I) ions by ascorbic acid as a weak reducer, which was added both to urine sample and mobile phase, respectively. A hydrophobic copper(I)–neocuproine chelate was determined by RP-LC–UV/VIS using a monolithic column Chromolith Performance RP-8e (100 × 4 mm I.D.) at 30.0 ± 0.1 °C with a methanol: aqueous buffer (pH 5.9, ammonium acetate and ascorbic acid 2.8 mmol L^?1) mobile phase at flow rate of 2.00 mL min^?1. Sample injection volume was 20 μL and detection was done at 453 nm. The method was validated over a concentration range of 0.09–11.50 μmol L^?1. The LOD of copper in human urine was found to be 0.07 μmol L^?1 concentration level, suitable for clinical analysis. The precision of the results, reported as the RSD, was below 4.6 % for copper concentration within range 0.5–5.0 μmol L^?1 in the spiked human urine samples.     

Determination of Betamethasone and Dexamethasone in Human Urine and Serum by MEKC After an Experimental Design

A simple and reliable micellar electrokinetic capillary chromatography method has been presented for the simultaneous determination of betamethasone (BM) and its epimer dexamethasone (DM) in human urine and serum. A three level full factorial experimental design was employed to search for the optimum conditions. Rapid and baseline separation of BM and DM was obtained within 7 min with the optimum conditions of 30 mM borax buffer, 30 mM sodium dodecyl sulfate at pH 10.0, separation voltage at 18 kV, injection time 15 s at a height of 10 cm, using sodium sorbate as internal standard. The proposed method was validated with respect to stability, precision, linearity and accuracy. Good relationship between peak area ratio and analyte concentration was linear over 30–1,000 µg mL^?1 for BM and DM with correlation coefficients ≥0.9993. Relative standard deviations of the method were all less than 4.50% in the intra-day and inter-day analysis. The developed method was applied to assay spiked human urine and serum samples containing both compounds with recoveries in the range of 97.5–100.5%.     

Development and Validation of a Sensitive LC-MS/MS Method for the Simultaneous Analysis of Three-Tropane Alkaloids in Blood and Urine

A simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous analysis of three tropane alkaloids in blood and urine. After 1 mL of a blood or urine sample was extracted using a liquid–liquid extraction method with ethyl acetate at pH 8 and homatropine as the internal standard, the tropane alkaloids were separated. An Allure PFP propyl column (50 mm × 2.1 mm, 5 µm) separated the tropane alkaloids using an acetonitrile-buffer solution (20 mmol/L ammonium acetate and 0.1% formic acid, pH 4) (70:30) as the mobile phase at a flow-rate of 0.2 mL/min in isocratic mode, with the LC-MS/MS in the positive ionization mode. For each compound, detection was related to two daughter ions (scopolamine: m/z 304.4 → 138.1 and 155.9; atropine: m/z 290.3 → 124.0 and 93.1; anisodamine: m/z 306.3 → 140.1 and 91.1; and homatropine: m/z 276.3 → 124.3 and 142.1). The tropane alkaloids exhibited excellent linearity in the range of 0.05–100 ng/mL in blood and 0.2–100 ng/mL in urine, with a limit of detection range from 0.02 to 0.05 ng/mL for biological materials. The extraction recoveries of atropine, scopolamine, and anisodamine were more than 53% in the blood and urine; the interday and intraday RSDs were less than 10%; the within-day and between-day accuracy were between ?9.8% and +8.8%. The present method is simple and rapid, as shown by its application to a clinical case. This method is useful for routine analysis of tropane alkaloids in cases of suspected tropane alkaloid poisoning.     

LC Method for the Determination of Rhaponticin in Rat Plasma, Faeces and Urine for Application to Pharmacokinetic Studies

A simple liquid chromatography (LC) method has been developed and validated to determine rhaponticin in rat plasma, faeces and urine. Chromatographic separation was achieved through mobile phase consisting of acetonitrile and water at a flow rate of 1.0 mL min^?1. Rhaponticin was quantified using UV detection at 324 nm. The assay was linear over the concentration range of 50–4,000 ng mL^?1 for plasma, faeces and urine. The intra- and inter-day RSD were less than 10%. The plasma, faeces and urine rhaponticin levels were monitored in rats after oral administration. This simple LC method appears to be useful in the pharmacokinetic investigation of rhaponticin.     

Determination of nerve agent metabolites in human urine by isotope-dilution gas chromatography-tandem mass spectrometry after solid phase supported derivatization

A simple and sensitive method has been developed and validated for determining ethyl methylphosphonic acid (EMPA), isopropyl methylphosphonic acid (IMPA), isobutyl methylphosphonic acid (iBuMPA), and pinacolyl methylphosphonic acid (PMPA) in human urine using gas chromatography-tandem mass spectrometry (GC-MS/MS) coupled with solid phase derivatization (SPD). These four alkyl methylphosphonic acids (AMPAs) are specific hydrolysis products and biomarkers of exposure to classic organophosphorus (OP) nerve agents VX, sarin, RVX, and soman. The AMPAs in urine samples were directly derivatized with pentafluorobenzyl bromide on a solid support and then extracted by liquid–liquid extraction. The analytes were quantified with isotope-dilution by negative chemical ionization (NCI) GC-MS/MS in a selected reaction monitoring (SRM) mode. This method is highly sensitive, with the limits of detection of 0.02 ng/mL for each compound in a 0.2 mL sample of human urine, and an excellent linearity from 0.1 to 50 ng/mL. It is proven to be very suitable for the qualitative and quantitative analyses of degradation markers of OP nerve agents in biomedical samples.     

Quantification of five neonicotinoids in human urine by modified QuEChERS with isotope dilution mass spectrometry: a preliminary study for the development of certified reference material

ABSTRACT

A study for the quantification method of neonicotinoid pesticides (Neos) in human urine that aims to develop the certified reference material (CRM) in the future was carried out. A modified Quick, Easy, Cheap, Effective, Rugged and Safe (QuEChERS) method based on dispersive solid phase extraction (d-SPE) with isotope dilution mass spectrometry (IDMS) was evaluated for the quantification of five Neos (acetamiprid, dinotefuran, imidacloprid, thiacloprid and thiamethoxam) in human urine control by optimisation of the extraction solvent, and the type and amount of d-SPE material. Two types of human urine controls (sample A and B) containing 5 μg/kg and/or 25 μg/kg of Neos were prepared and employed for this study. The results of spike test using sample A (2 mL) obtained by modified QuEChERS method with acetone extraction (10 mL) and d-SPE using a strong cation exchanger (silica gel modified with benzenesulphonic acid phase, SCX) 500 mg were as follows: 97.8%–103.1% for 5 μg/kg and 97.2%–102.7% for 25 μg/kg (described as percentage by the quantification results of IDMS relative to the spiked amount of pesticides). These results were comparable to those by SPE cartridge method using SCX functionalised hydrophilic styrene divinylbenzene (PCX). The repeatabilities of the analyses, represented as relative standard deviations, were also comparable for spike level 5 μg/kg and 25 μg/kg of Neos: 0.1%–7.2% for modified QuEChERS with IDMS and 0.2%–5.6% for PCX cartridge method. The results of spike test using sample B for a spike level 5 μg/kg were 96.0%–100.6%. These results indicate that modified QuEChERS method with IDMS can be used for the development of certified reference material and has the potential to use for the quantification of Neos in real human urine.     

Determination of lewisite metabolite 2-chlorovinylarsonous acid in urine by use of dispersive derivatization liquid-liquid microextraction followed by gas chromatography–mass spectrometry

The purpose of this study was to develop a sensitive and simple method, based on dispersive derivatization liquid-liquid microextraction–gas chromatography–mass spectrometry (DDLLME–GC–MS) in scanning and selected-ion-monitoring (SIM) modes, for detection of 2-chlorovinylarsonous acid (CVAA) as a hydrolysis product and urinary metabolite of lewisite in urine samples. Chloroform (65 μL), methanol (500 μL), and ethanedithiol (10 μL) were used as extraction solvent, dispersive solvent, and derivatizing reagent, respectively. Critical conditions of the proposed method were optimized. The nucleophilic reactions of dithiol and monothiol compounds with CVAA were also studied using a competitive method. In view of the high affinity of trivalent arsenic for sulfhydryl groups, the interaction between CVAA and bis(2-chlorovinyl)arsonous acid (BCVAA) and free cysteine (Cys) was also investigated using liquid chromatography–electrospray ionization mass spectrometry (LC–ESI-MS). The interference of Cys, present in human urine, with the detection of CVAA was evaluated using dithiol and monothiol chemicals as derivatization agents. The developed method provided a preconcentration factor of 250, and limits of detection of 0.015 and 0.30 μg L^?1 in SIM and scanning modes, respectively. The calibration curves were linear over the concentration range of 1–400 μg L^?1 in full-scan mode. The relative standard deviation (RSD) values were calculated to be 5.5 and 3.2 % at concentrations of 20 and 100 μg L^?1, respectively. Collision-induced dissociation studies of the major electron-impact (EI) ions were performed to confirm the proposed fragment structure of CVAA-dithiols derivatives. Results indicated that the developed method for analysis of CVAA is suitable not only for verification of human exposure to lewisite, but also for quantification of CVAA in urine samples.

A Simple and Sensitive LC–MS/MS Method for Simultaneous Determination of Temsirolimus and Its Major Metabolite in Human Whole Blood

A simple, fast and sensitive LC–MS/MS method was developed and validated for the simultaneous determination of the concentrations of temsirolimus and its major metabolite, sirolimus, in human whole blood. The blood sample (100 μL) after adding temsirolimus-d7 and sirolimus-d3 internal standards was precipitated with 0.200 mL of methanol/0.300 M zinc sulfate (70/30, v/v), then analyzed by a Shimatzu LC system coupled to a Sciex API-5000 mass spectrometer. The chromatographic separation was carried out on a BDS Hypersil C8 column (50 × 3.0 mm, 5 μm) at 50 °C with a mobile phase composed of methanol/water/formic acid (72/28/0.1) (v/v/v) containing 2.50 mM ammonium acetate. Mass spectrometric detection was performed using electrospray positive ionization with multiple reaction monitoring mode. This method was validated from 0.250 to 100 ng mL⁻¹ for temsirolimus and 0.100 to 40.0 ng mL⁻¹ for sirolimus. The lower limits of quantitation were 0.25 ng mL⁻¹ for temsirolimus and 0.1 ng mL⁻¹ for sirolimus. The intra-day and inter-day precisions (CV %) of spiked quality control (QC) samples were less than 10.4 and 9.6 %, respectively. The accuracies as determined by the relative error for QC samples were less than 12.1 % for intra-day and 7.3 % for inter-day. No significant matrix effect was observed. This method has been successfully applied to analyze clinical pharmacokinetic study samples. The assay reproducibility was also demonstrated by using incurred samples.

     

Quantitative determination of free and total bisphenol A in human urine using labeled BPA glucuronide and isotope dilution mass spectrometry

Bisphenol A (BPA) is a widely used industrial chemical in the manufacturing of polycarbonate plastic bottles, food and beverage can linings, thermal receipts, and dental sealants. Animal and human studies suggest that BPA may disrupt normal hormonal function and hence, potentially, have negative effects on the human health. While total BPA is frequently reported, it is recognized that free BPA is the biologically active form and is rarely reported in the literature. The objective of this study was to develop a sensitive and improved method for the measurement of free and total BPA in human urine. Use of a labeled conjugated BPA (bisphenol A-d6 β-d-glucuronide) allowed for the optimization of the enzymatic reaction and permitted an accurate determination of the conjugated BPA concentration in urine samples. In addition, a ¹³C₁₂-BPA internal standard was used to account for the analytical recoveries and performance of the isotope dilution method. Solid-phase extraction (SPE) combined with derivatization and analysis using a triple quadrupole GC-EI/MS/MS system achieved very low method detection limit of 0.027 ng/mL. BPA concentrations were measured in urine samples collected during the second and third trimesters of pregnancy in 36 Canadian women. Total maternal BPA concentrations in urine samples ranged from not detected to 9.40 ng/mL (median, 1.21 ng/mL), and free BPA concentrations ranged from not detected to 0.950 ng/mL (median, 0.185 ng/mL). Eighty-six percent of the women had detectable levels of conjugated BPA, whereas only 22 % had detectable levels of free BPA in their urine. BPA levels measured in this study agreed well with data reported internationally.     

Liquid Chromatographic Method with Ultraviolet Absorbance Detection for Measurement of Rimonabant in Human Plasma

Abstract

Rimonabant is a selective cannabinoid CB1 receptor antagonist licensed in Europe for treatment of obesity when a risk factor is associated. The objective of this study was to develop and validate a method for measurement of rimonabant in human plasma using high-performance liquid chromatography coupled to an ultraviolet (UV) detector. Rimonabant and loxapine (internal standard) were extracted from 500 µL of plasma. Chromatography was performed on a 250 mm × 4.6 mm C18 column using a mobile phase constituted of 0.05 M ammonium acetate/methanol (25:75, v/v) at a flow rate of 1 ml/min followed by UV detection at 250 nm. Calibration curves covered a range from 13 (lower limit of quantification) to 1000.0 ng/mL. Validation results demonstrated that rimonabant could be accurately and precisely quantified in human plasma. Limit of quantification was 13 ng/mL. This simple method can be used for measuring rimonabant concentrations in human plasma in clinical practice.     

Trace Determination of Manganese in Urine by Graphite Furnace Atomic Absorption Spectrometry and Inductively Coupled Plasma–Mass Spectrometry

This paper describes a simple and sensitive method for the determination of manganese in human urine by graphite furnace atomic absorption spectroscopy (GFAAS), which includes sample preparation by microwave digestion. Matrix modifier combinations, the digestion power, pyrolysis, and atomization temperatures were optimized. A mixture of 5.0 µg Pd(NO₃)₂ and 3.2 µg Mg(NO₃)₂ modifier presented the best performance. The optimal temperatures for pyrolysis and atomization were 1500°C and 1950°C, respectively. The GFAAS method was compared to inductively coupled plasma–mass spectrometry (ICP–MS) for the determination of manganese in urine. Analytical figures of merit for GFAAS and ICP–MS were: accuracy (3.46%, 2.19%), precision (3.61%, 5.84%), LOD (0.109 µg · L^?1, 0.015 µg · L^?1), LOQ (0.327 µg · L^?1, 0.045 µg · L^?1), and recovery (80–100%, 74–89%). Both methods were employed for the determination of Mn in urine and the results were compared statistically.